MARKET

VCNX

VCNX

Vaccinex Inc
NASDAQ
5.80
+0.79
+15.86%
Opening 14:54 04/25 EDT
OPEN
5.75
PREV CLOSE
5.01
HIGH
5.80
LOW
5.46
VOLUME
7.70K
TURNOVER
0
52 WEEK HIGH
100.80
52 WEEK LOW
4.432
MARKET CAP
9.19M
P/E (TTM)
-0.1328
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Processa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. Cyclacel Pharmaceuticals stock rose 23.04% and Compass Therapeutics shares rose 21.62%. Can Fite Biofarma (AMEX:CANF) stock also moved upwards.
Benzinga · 15h ago
Weekly Report: what happened at VCNX last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at VCNX last week (0408-0412)?
Weekly Report · 04/15 09:31
Weekly Report: what happened at VCNX last week (0401-0405)?
Weekly Report · 04/08 09:33
Vaccinex Q4 EPS $(0.33) Up From $(23.10) YoY
Benzinga · 04/03 02:59
Vaccinex files to sell 433.5K common shares for holders
Healthcare Vaccinex files to sell 433.5K common shares for holders Apr. 02, 2024 4:21 PM ETVaccinex, Inc. (VCNX) Stock. The company filed a prospectus related to the proposed resale of 433. 5K common Shares.
Seeking Alpha · 04/02 20:21
VCNX Stock Earnings: Vaccinex Reported Results for Q4 2023
Vaccinex reported earnings per share of -33 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. Vaccinex has a market value of less than $1.5 billion. The stock is down 1.7% today.
Investorplace · 04/02 17:52
Vaccinex reports Q4 results
Vaccinex reports Q4 results. Raised $17.9 million of new financing during Q4 2023 and Q1 2024. Cash and cash equivalents and marketable securities on December 31, 2023 were $1.5 million. Vaccinex, Inc. (VCNX)
Seeking Alpha · 04/02 14:09
More
About VCNX
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.

Webull offers Vaccinex Inc stock information, including NASDAQ: VCNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VCNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VCNX stock methods without spending real money on the virtual paper trading platform.